TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Ataxin 3 Levels in Cerebrospinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Ataxin 3 Levels in Blood Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative angiographic occlusion rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complications of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-Day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of Atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage Change in MRI-PDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of metaphase II oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in area under the concentration-time curve (AUC0-t) for midazolam and 1-OH-midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area under the concentration-time curve (AUC0-inf) for midazolam and 1-OH-midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum plasma concentration (Cmax) for midazolam and 1-OH-midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration observed at the end of the dosing interval (Ctrough) for plasma PBI-4050 and its major metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in severity of AKN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's notes improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Microbiota composition change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of C-reactive protein, fibrinogen, erythrosedimentation rate and white blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intracardiac anatomic site target acquisition success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of SCAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in Psoriasis Area and Severity Index (PASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of recurrent lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Perceived stress level from baseline to post stress period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment-related Changes in Vocal Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-related Changes in Speech Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental and Physical Effort Associated With Each Treatment Program
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants With a Complete Response or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with fasting blood glucose checked
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with cholesterol checked
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes of A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in microbiological count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of the reaching movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-efficacy for symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in self-efficacy for quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neuro-developmental status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peanut allergy reaction severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emotion scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy for coping with cancer
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RT-PCR measurement of IL-17 in lesional psoriasis skin samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Participants who Utilize the Decision Aid
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percent Positive Agreement of Macimorelin-GHST with ITT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Negative Agreement of Macimorelin-GHST with ITT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in calcium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Objectively Assessed Physical Activity at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Objectively Assessed Physical Activity at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: optimal scan protocol effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of delayed gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects Reporting Laboratory Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of acute colorectal cancer surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative 1-year mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: competency in urethrocystoscopy skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in Rheumatoid Arthritis Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antiviral activity (change from baseline in HBV DNA (log 10))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucagon Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Adolescent WTP Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Parent WTS Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety events of interest
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Control Without Rescue Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summary score from a Cognitive Neurophysiological Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative Irritation Score (CIS10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Presence of pulmonary edema on chest X ray at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of primary graft dysfunction at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Microbiome differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Intra-operative and Post-operative Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement between subjective refraction measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social disconnection
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Respiratory amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lowering Eye Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraday glycemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowering cardiovascular risks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of elevated blood pressure condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: profile of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients Reporting Satisfaction with Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Health Care Providers Reporting Satisfaction with Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of grade 3 and 4 thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Surface Ocular Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination of post-radiation salivary fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: amount of fat tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of first RV episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RV-related resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diarrhea-related resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacodynamic effect by pH monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Academic stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rapid Assessment Physical Activity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with vancomycin AUC/MIC ≥ 400 and serum trough concentration ≤ 20 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial cervical opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for further dilatation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bladder and Rectal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of minor and major bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in adipose tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour energy expenditure (kilocalories/minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caregiver Understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver Follow-through
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration (Cmax) in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference of fasting blood glucose (FBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean difference of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean difference of fasting serum insulin (FSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annualized Rate of Severe Exacerbation Events
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change From Baseline in Pre-Bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with an average of ≥3 SCBM/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of Ketoconazole 2% Foam in treating Tinea Versicolor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in KOOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development of pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Prediction of preterm labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal serum lipid profile off lipid lowering agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintain CD4 counts > 75% of baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of the last measured concentration above the limit of quantification (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fully Vaccinated Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well Child Care Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specific Image-Based Airway Volume (siVaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnosis confirmation of current asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in 24h-aortic systolic-blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in sleep efficiency (%)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Core ADHD symptoms (inattention/hyperactivity/impulsivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conners Psychopathology Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fasting non-HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported measure of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDT (ondansetron level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving minimal or clear PGA score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety & Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: production and clearance rates of intestinal and hepatic TRL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident event rate for all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incident event rate for non-fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident event rate for non-fatal ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ADAS-ADL
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Serum Calcium Level Over 11.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Scar scale (VSS and BIQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Perceived benefits scale (PBS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distress Thermometer and Problem List (DT)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improving adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improving coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: safety of diclofenac and HPβCD
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetics of diclofenac and HPβCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrence of symptoms requiring additional surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Early death following surgery
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (Arm A)
Endpoint domain: Mortality/survival
Primary endpoint: Progression Free Survival (Arm B)
Endpoint domain: Mortality/survival
Primary endpoint: Objective Pain Scale (OPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the ulcerative colitis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of the Crohn's disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of subtypes of acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Insulin aspart antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean reduction of darkness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Horizontal Bone Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone Width Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Who Achieved a Raymond Score I/II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Experienced Neurological Death
Endpoint domain: Mortality/survival
Primary endpoint: Participants With An Adjudicated On-trial Relapse
Endpoint domain: Mortality/survival
Primary endpoint: Visual acuity early post operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity after 3 months post operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic Outcome
Endpoint domain: Mortality/survival
Primary endpoint: Total Number of Serrated Lesions Proximal to the Sigmoid Colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Serrated Lesions Proximal to the Sigmoid Colon Per Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: extubation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of participants able to complete the PET/MRI examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration-effect relationship of adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of child behavioral problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline BSS at Day 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With 50% Reduction in Corticosteroid Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Newly-Diagnosed HIV Infection
Endpoint domain: Mortality/survival
Primary endpoint: upgrade rates related to histologic subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Disease Activity Based on Simplified Disease Activity Index (SDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Disease Activity Score Based on 28-joints Count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target-to-background ratio (TBR) uptake of 18F-NaF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Success Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes